Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $12.00

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.00.

A number of equities analysts have recently commented on NEO shares. TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price target on shares of NeoGenomics in a report on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Leerink Partners set a $14.00 target price on shares of NeoGenomics in a research report on Tuesday, October 28th. Finally, Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th.

Insider Buying and Selling

In other news, EVP Alicia C. Olivo sold 20,916 shares of NeoGenomics stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the sale, the executive vice president owned 31,083 shares of the company’s stock, valued at approximately $372,996. This trade represents a 40.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Warren Stone sold 22,128 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares of the company’s stock, valued at $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds have recently made changes to their positions in NEO. First Horizon Corp increased its stake in NeoGenomics by 52.6% in the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 865 shares during the period. Aster Capital Management DIFC Ltd boosted its holdings in NeoGenomics by 42.5% during the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 997 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of NeoGenomics by 68.2% in the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,460 shares during the period. Headlands Technologies LLC acquired a new position in shares of NeoGenomics in the 2nd quarter worth approximately $32,000. Finally, Holos Integrated Wealth LLC acquired a new position in shares of NeoGenomics in the 4th quarter worth approximately $76,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Trading Up 2.1%

NASDAQ:NEO opened at $12.31 on Thursday. The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41. The company’s 50 day moving average is $12.28 and its 200-day moving average is $9.68. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -13.99 and a beta of 1.58. NeoGenomics has a 12 month low of $4.72 and a 12 month high of $14.73.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.